The fierce competition coming from generic drug companies, the escalating costs of developing new drugs and the arduous process of getting them approved weighs heavily on Sanofi (OTCQB: SNYNF) and its competitors.
During a conference call last week, Sanofi's CEO Chris Viehbacher admitted that the pharmaceutical company has not brought a lot of new products to the market over the last 10 years, according to PMLiVE.
The scrutiny of the company's R&D track record was one of the subjects that came up on Sanofi's fourth-quarter results call last week where Viehbacher at the same time defended the company’s current product development saying it has "one of the better pipelines in the industry."
Still Has Strong Pipeline
To that point, Sanofi currently has nine late-stage projects that may potentially be filed over the next 4 years in several disease areas, including diabetes, vaccines, cardiovascular and immunology. This comes on the heels of a reduction in the firm's R&D headcount from 15,000 to 9,000.
The Paris-based company’s stock gained some ground Feb 7, 2014, closing at $96.96, up $1.96 cents from the share price of 95.00 the previous day. Its volume soared with 113,366 shares changing hands, nearly five times its three-month average of 23,779 shares.
The pharmaceutical giant and maker of various healthcare products also announced recently that one of its wholly-owned subsidiaries, Genzyme, is partnering with Alnylam Pharmaceuticals, Inc. to develop and commercialize treatments for rare genetic diseases. As part of the expanded relationship, Genzyme will invest $700 million to become a major Alnylam shareholder, according to the company’s written statement.
Under the new agreement, Genzyme will have significant rights to Alnylam's portfolio of clinical and pre-clinical stage drug candidates.
“This collaboration is an important building block for our future. It strengthens our pipeline and provides us with the opportunity to meet the needs of patients with rare diseases around the world through our well-established global organization.” Genzyme's President and CEO David Meeker said in a written statement.
Find out what could be the best investor’s move when it comes to RYDAF by getting the complete report here, or by cutting and pasting the following link in your Web browser:
Alaska Drilling Still Up In the Air
Whether a recent federal court ruling will scrap Royal Dutch Shell Plc (OTCQB: RYDAF) Alaska drilling plans remains to be seen, but the uncertainty it creates could affect the oil company’s share price.
The oil company’s plans to drill for oil off the coast of Alaska could be delayed because of a US appeals court opinion that the government acted illegally by opening up nearly 30-million acres of US Arctic waters.
Environmental groups are declaring the ruling made by the 9th Circuit Court of Appeals in the U.S. as a solid win in their attempt to nix new drilling by Shell in the Alaskan wilderness. Shell has not responded to the decision, only saying its lawyers are “reviewing the opinion,” according to published reports. Some industry experts believe it would be premature to count Shell out.
On Feb. 7, RYDAF share price closed at $34.35, up 15 cents from the share price of $34.20 the previous day.
Launches New Cloud-Based App
FUJIFILM Holdings Corp. (OTCPINK:FUJIY) announced Feb 6, 2014 that it has launched both free and paid versions of SkyDesk Projects-an app that supports project management-for use on the Company's cloud-based business communication support service.
According to Fujifilm, SkyDesk Projects offers an environment for a group of members to efficiently work together on a project. The app's features include setting forums, tasks, meetings, project members' roles, as well as a file sharing feature to manage documents. Members can also receive feeds about information on the project he/she belongs to.
These basic functions are available in the free version, while the paid version, SkyDesk Projects Premium, provides more effective usability for large-scale organizations with optional functions such as Bug Tracker and Online Group Chat.
On Feb. 7 FUJIY share price closed at $28.09, down 9 cents from the share price of $27.90 the previous day.
Find out what could be the best investor’s move when it comes to FUJIY by getting the complete report here, or by cutting and pasting the following link in your Web browser:
Promising Drugs in the Pipeline
Provectus Pharmaceuticals (OTC: PVCT) share price closed at $1.77, down 4 cents from the share price of $1.81cents the previous day.
The development-stage pharmaceutical company is developing medicines for oncology and dermatology applications. Provectus product line includes PV-10, a Phase II study completed drug candidate for metastatic melanoma, a Phase I study completed candidate for breast cancer, and a Phase I protocol expansion candidate for liver metastasis.
In addition it is conducting PH-10, a Phase IIc randomized study initiated drug candidate for the treatment of psoriasis, and Phase II study completed candidate for atopic dermatitis. It also develops PH-10 for the treatment of actinic keratosis and severe acne vulgaris.
Moreover, the company develops over-the-counter pharmaceuticals, including GloveAid, a hand cream with antiperspirant and antibacterial properties; Pure-ific line of products to prevent the spread of germs on skin; and Pure-Stick and Pure N Clear acne products.
Find out what could be the best investor’s move when it comes to PVCT by getting the complete report here, or by cutting and pasting the following link in your Web browser:
Sixfigurestockpicks.com issues momentum alerts on stocks that can provide gains to day traders.
Sixfigurestockpicks.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.
Sixfigurestockpicks.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals DailyStockMotion.com is often in the know of several large investor awareness campaigns being deployed. Timing is everything when trading Penny Stocks. Gain an Edge by joining the Sixfigurestockpicks.com newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership. Simply sign up for free and start receiving exclusive alerts. Subscribe Here: http://www.sixfigurestockpicks.com/ Disclosure
Sixfigurestockpicks.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.